<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H56CC9DCBDE9B45908D2152C36A9052C9" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 7630 IH: Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-04-28</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7630</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220428">April 28, 2022</action-date><action-desc><sponsor name-id="M001157">Mr. McCaul</sponsor> (for himself, <cosponsor name-id="S001175">Ms. Speier</cosponsor>, <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>, and <cosponsor name-id="K000376">Mr. Kelly of Pennsylvania</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.</official-title></form><legis-body id="H3B2A5B7C5AC44D168CC7EDC6E1F1C4C4" style="OLC"><section id="HE6A87ECDDE6E43EC9AB2BECA524C87E1" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022</short-title></quote> or the <quote><short-title>Childhood Cancer STAR Reauthorization Act of 2022</short-title></quote>.</text></section><section id="H45321FA584C04A43A35A45F397A458E7"><enum>2.</enum><header>Reauthorizing and improving the Childhood STAR Act</header><subsection id="H3C9B769387EF407FAAD53C672DCAF3F9"><enum>(a)</enum><header>Children's cancer biorepositories</header><text>Section 417E of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/285a-11">42 U.S.C. 285a–11</external-xref>) is amended—</text><paragraph id="HF7BE8AAEC5BA4902983BDACFDBD4D5DF"><enum>(1)</enum><text>in subsection (a)—</text><subparagraph id="H9FBAE4573A1D44C7823C2D240A0BAB52"><enum>(A)</enum><text>in paragraph (2)(A), by inserting before the period at the end of the second sentence the following: <quote>, and providing sample collection incentives for both solid tumor cancer and paired tissues for all pediatric cancers</quote>; </text></subparagraph><subparagraph id="H305B57B5C1D44BD8B0B2746689EC4EF0"><enum>(B)</enum><text>in paragraph (9), by striking <quote>Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018</quote> and inserting <quote>Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022</quote>; </text></subparagraph><subparagraph id="H7761EEB8E94D4413933270DF17D0444E"><enum>(C)</enum><text>by redesignating paragraph (10) as paragraph (11); and</text></subparagraph><subparagraph id="HAE4328ADAEE6455F8AC14E1791186289"><enum>(D)</enum><text>by inserting after paragraph (9) the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H3AFA49597FD34D86BF9F947E8F0F879D"><paragraph id="H5771A3372E6247239F50BEF139453365" commented="no"><enum>(10)</enum><header>Report on researcher access to children's cancer biorepository samples</header><text>The Director of NIH shall, not later than 2 years after the date of enactment of the <short-title>Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022</short-title>, submit to Congress a report on policy changes that would facilitate streamlining the approval process for researcher access to children's cancer biorepository samples, with a special focus on lowering the regulatory burden before samples can be sent to investigators.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H2E2FA251D0D948239F7A5159D885F144"><enum>(2)</enum><text>in subsection (d), by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></paragraph></subsection><subsection id="HF58F84B862394FAFB1E9E3A8211F42CA"><enum>(b)</enum><header>Cancer survivorship programs</header><text>Section 201 of the Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018 (<external-xref legal-doc="public-law" parsable-cite="pl/115/180">Public Law 115–180</external-xref>) is amended—</text><paragraph id="HC5394AC20FC344B29F4322B9F9BE5D95"><enum>(1)</enum><text>in subsection (a)—</text><subparagraph id="HCA760B43E81340D38BE5B743E162D9C0"><enum>(A)</enum><text>in paragraph (1), by striking <quote>may make awards</quote> and inserting <quote>shall make awards</quote>; and</text></subparagraph><subparagraph id="H8BE9E9D8502F473BAD364B9CE740E5D4"><enum>(B)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HE57A13CA9E4B4A3189A8871709D6FF5B"><paragraph id="H9464A45429554BA48DC40AB37181167E"><enum>(4)</enum><header>Consideration</header><text>In developing, studying, and evaluating model systems pursuant to this subsection, recipients of awards under this subsection shall give particular consideration to the report issued by the Agency for Healthcare Research and Quality in February 2022, titled <quote>Models of Care That Include Primary Care for Adult Survivors of Childhood Cancer: A Realist Review</quote>.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="HE037363F987346C49BB769FBF9D015FF"><enum>(2)</enum><text>in subsection (b), in paragraphs (1) and (2), by striking <quote>date of enactment of this Act</quote> each place it appears and inserting <quote>date of enactment of the <short-title>Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022</short-title></quote>.</text></paragraph></subsection><subsection id="HD0AECC9AA0E345ED8788B373C8E2B0A3"><enum>(c)</enum><header>Survivorship electronic health records</header><text>The Secretary of Health and Human Services shall coordinate with the Office of the National Coordinator for Health Information to prepare a report on the role that tailored survivorship electronic health records can play in life-long health care for childhood cancer survivors, with a special focus on survivors who face unique lifelong health needs and late effects as they transition to primary care. Such report shall be submitted to Congress not later than 2 years after the date of enactment of this Act.</text></subsection><subsection id="H7310B24974E641D7A9B1017079C5EA09"><enum>(d)</enum><header>Sense of Congress regarding the creation of a childhood cancer medical code</header><text display-inline="yes-display-inline">It is the sense of Congress that the National Center for Health Statistics at the Centers for Disease Control and Prevention and the Centers for Medicare &amp; Medicaid Services should consider adding a new Childhood Cancer Code to the International Classification of Diseases (ICD) system for the purpose of facilitating access to existing insurance coverage of childhood cancer patients and survivors, as appropriate. </text></subsection></section></legis-body></bill> 

